Suchergebnisse - "Maschmeyer, Georg"

PubPharm (15)

1

Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74)

enthalten in: Annals of hematology | 2021

von Krüger, W. | Hirt, C. | Basara, N. | +10

2

PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18) : follow-up analysis of an international, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Haematology | 2021

von Kreissl, S. | Goergen, H. | Buehnen, I. | +32

3

Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma : a secondary analysis of a randomized clinical trial

enthalten in: Journal of cancer research and clinical oncology | 2019

von Budau, L. | Wilhelm, C. | Moll, R. | +9

4

Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial

enthalten in: Journal of cancer research and clinical oncology | 2019

von Budau, L. | Wilhelm, C. | Moll, R. | +9

5

Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial

enthalten in: Journal of cancer research and clinical oncology | 2019

von Budau, L. | Wilhelm, C. | Moll, R. | +9

6

Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial

enthalten in: Journal of cancer research and clinical oncology | 2019

von Budau, L. | Wilhelm, C. | Moll, R. | +9

7

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP : results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial

enthalten in: Annals of hematology | 2019

von Hüttmann, A. | Rekowski, J. | Müller, S. | +50

8

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial

enthalten in: Annals of hematology | 2019

von Hüttmann, A. | Rekowski, J. | Müller, S. | +50

9

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial

enthalten in: Annals of hematology | 2019

von Hüttmann, A. | Rekowski, J. | Müller, S. | +50

10

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial

enthalten in: Annals of hematology | 2019

von Hüttmann, A. | Rekowski, J. | Müller, S. | +50